The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases

Journal of Immunology

Volumn 171, Issue 5, 2003, Pages 2402-2412

  Caldwell, Sheila A ^a   Ryan, Mary H ^a   McDuffie, Elwood ^a   Abrams, Scott I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FAS LIGAND; GAMMA INTERFERON; GRANZYME A; GRANZYME B; PERFORIN; TUMOR NECROSIS FACTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; LUNG METASTASIS; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION; TUMOR REGRESSION; TUMOR REJECTION;

EID: 0041929457     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.5.2402     Document Type: Article

References (38)

1. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1440.
2. Van Parijs, L., and A. K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243.
3. Shulze-Osthoff, K., D. Ferrari, M. Los, S. Wesselborg, and M. E. Peter. 1998. Apoptosis signaling by death receptors. Eur J. Biochem. 254:439.
4. Krammer, P. H. 1999. CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 71:163.
5. Siegel, R. M., F. K. Chan, H. J. Chun, and M. J. Lenardo. 2000, The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1:469.
6. Henkart, P. A. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343.
7. Russell, J. H., and T. J. Ley. 2002. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20:323.
8. Sarin, A., E. K. Haddad, and P. A. Henkart. 1998. Caspase dependence of target cell damage induced by cytotoxic lymphocytes. J. Immunol. 161:2810.
9. + CTL reactive against tumor cells expressing a naturally-occurring rejection epitope. J. Immunol. 167:4286.
10. DeLeo, A. B., H. Shiku, T. Takahashi, M. John, and L. J. Old. 1977. Cell surface antigens of chemically induced sarcomas of the mouse. I. Mouse leukemia virus related antigens and alloantigens on cultured fibroblasts and sarcomas: description of a unique antigen on BALB/c Meth A sarcoma. J. Exp. Med. 146:720.
11. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
12. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734.
13. Winter, H., H. M. Hu, W. J. Urba, and B. A. Fox. 1999. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J. Immunol. 163:4462.
14. Peng, L., J. C. Krauss, G. E. Plautz, S. Mukai, S. Shu, and P. A. Cohen. 2000. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-γ mechanisms that cannot be predicted from in vitro T cell characteristics. J. Immunol. 165:7116.
15. Helmich, B. K., and R. W. Dutton. 2001. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of TC1 and TC2 effectors. J. Immunol. 166:6500.
16. Hobeika, A. C., T. M. Clay, P. J. Mosca, H. K. Lyerly, and M. A. Morse. 2001. Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit. Rev. Immunol. 21:287.
17. Seki, N., A. D. Brooks, C. R. Carter, T. C. Back, E. M. Parsoneault, M. J. Smyth, R. H. Wiltrout, and T. J. Sayers. 2002. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168:3484.
18. van den Broek, M. E., D. Kagi, F. Ossendorp, R. Toes, S. Vamvakas, W. K. Lutz, C. J. Melief, R. M. Zinkernagel, and H. Hengartner. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184:1781.
19. + T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell. Immunol. 182:137.
20. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156:3678.
21. + CTL. J. Immunol. 164:4941.
22. Mule, J. J., J. C. Yang, R. Lafreniere, S. Shu, and S. A. Rosenberg. 1987. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J. Immunol. 139:285.
23. Moller, P., K. Koretz, F. Leithauser, S. Bruderlein, C. Henne, A. Quentmeier, and P. H. Krammer. 1994. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 57:371.
24. Owen-Schaub, L. B., R. Radinsky, E. Kruzel, K. Berry, and S. Yonehara. 1994. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54:1580.
25. Lee, J. K., T. J. Sayers, A. D. Brooks, T. C. Back, H. A. Young, K. L. Komschlies, J. M. Wigginton, and R. H. Wiltrout. 2000. IFN-γ-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J. Immunol. 164:231.
26. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
27. Pardoll, D. M. 2000. Therapeutic vaccination for cancer. Clin. Immunol. 95:S44.
28. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.
29. Greten, T. F., and E. M. Jaffee. 1999. Cancer vaccines. J. Clin. Oncol. 17:1047.
30. Cohen, P. A., L. Peng, J. Kjaergaard, G. E. Plautz, J. H. Finke, G. K. Koski, B. J. Czerniecki, and S. Shu. 2001. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit. Rev. Immunol. 21:215.
31. Keane, M. M. S. A. Ettenberg, G. A. Lowrey, E. K. Russell, and S. Lipkowitz. 1996. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56:4791.
32. Krammer, P. H., P. R. Galle, P. Moller, and K. M. Debatin. 1998. CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv. Cancer Res. 75:251.
33. Owen-Schaub, L., H. Chan, J. C. Cusack, J. Roth, and L. L. Hill. 2000. Fas and Fas ligand interactions in malignant disease. Int. J. Oncol. 17:5.
34. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J. L. Bodmer, M. Schroter, K. Burns, C. Mattmann, et al. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388:190.
35. Djerbi, M., V. Screpanti, A. I. Catrina, B. Bogen, P. Biberfeld, and A. Grandien. 1999. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190:1025.
36. Medema, J. P., J. de Jong, T. van Hall, C. J. Melief, and R. Offringa. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190:1033.
37. Kessler, B., D. Hudrisier, M. Schroeter, J. Tschopp, J. C. Cerottini, and I. F. Luescher. 1998. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production. J. Immunol. 161:6939.
38. Esser, M. T., B. Krishnamurthy, and V. L. Braciale. 1996. Distinct T cell receptor signaling requirements for perforin- or FasL-mediated cytotoxicity. J. Exp. Med. 183:1697.